{"nctId":"NCT00116207","briefTitle":"An Intervention Trial for Cardiac Neuropathy in Type 1 Diabetes","startDateStruct":{"date":"2000-01"},"conditions":["Diabetic Autonomic Neuropathy"],"count":44,"armGroups":[{"label":"ORAL ANTIOXIDANT","type":"EXPERIMENTAL","interventionNames":["Drug: ORAL ANTIOXIDANT"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: ORAL ANTIOXIDANT"]}],"interventions":[{"name":"ORAL ANTIOXIDANT","otherNames":["Allopurinol (300mg daily),","ALA (600mg twice daily)","nicotinamide (750 mg twice daily)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 1 diabetes\n* A1C \\<9%\n* Mild neuropathy\n* Mild retinopathy\n* Mild nephropathy\n\nExclusion Criteria:\n\n* History of drug or alcohol dependence, heart disease, viral illness, liver disease, advanced kidney disease\n* Pregnant or nursing\n* Severely overweight","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Global [11C]HED Retention Index (RI)","description":"Distal defects in \\[11C\\]meta-hydroxyephedrine (\\[11C\\]HED) retention involving at least 10 % of the left ventricle was used to define Cardiac Autonomic Neuropathy (CAN). The retention index (RI) is the unit of measure and is expressed as \\[11C\\]HEDblood min -1\\[ml tissue\\]-1\n\nPET Data of Randomized Subjects at Baseline and 24-Months\n\nThe primary outcome was the change in the global \\[11C\\]HED RI = measure of cardiac innervation at 24 months in participants taking the active drug compared with those on placebo.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.081","spread":"0.017"},{"groupId":"OG001","value":"0.073","spread":"0.016"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.070","spread":"0.018"},{"groupId":"OG001","value":"0.074","spread":"0.016"}]}]}]},{"type":"SECONDARY","title":"Global Coronary Flow Reserve as a Measure of Endothelial Function","description":"global myocardial blood flow reserve as a measure of endothelial function. Measured by PET using \\[13N\\]ammonia at rest and during adenosine stimulated coronary vasodilation.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.95","spread":"1.32"},{"groupId":"OG001","value":"2.94","spread":"1.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.02","spread":"1.82"},{"groupId":"OG001","value":"3.22","spread":"0.85"}]}]}]},{"type":"SECONDARY","title":"Systemic Oxidative Stress","description":"ng of 8-epi prostaglandin F2alpha /G creatinine assessed in 24 hour urine collection","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.92","spread":"1.99"},{"groupId":"OG001","value":"2.09","spread":"1.12"}]}]}]},{"type":"SECONDARY","title":"Inflammation","description":"High Sensitivity CRP (nmol/L)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.51","spread":"20.19"},{"groupId":"OG001","value":"16.95","spread":"18.38"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":22},"commonTop":["Non-Serious Adverse Events"]}}}